Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and SHR1020 in Advanced Melanoma
NCT05051865Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of famitinib in melanoma, sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
famitinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05051865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05051865.